McGrollumab With P-53 Mutation

The first study of Revuemenib was updated by Dr. Isor from MD-Innerson. And the response rate in this relapse refractory NPM1-mute and KMT2A, rearranged population was very good 53% overall response rate in the efficacy population,. 20% CRs, 10% CRH which is almost as good as a CR and a bunch of responses that didn't have count recovery. The drug was on hold for a while last year or the year before because of severe anemia's that occurred. But it'll be a side effect you can put up with. So now we're going to go on to a class of drugs that